Ecallantide

Summary

Ecallantide (CHEMBL1201837) is an approved protein (ATC B06AC03); indicated across 2 conditions including hereditary angioedema and angioedema.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: B06AC03
• Indications: 2 conditions
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201837
Name	Ecallantide
Type	Protein
Max phase	4
ATC	B06AC03

Also known as: DX-88, Ecalantida, Ecallantide, Escallantide, ECALLANTIDE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hereditary angioedema	4	MONDO:0019623	MONDO:0019623
angioedema	2	MONDO:0010481	EFO:0005532

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE2	6
PHASE3	3
PHASE2/PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00262080	PHASE3	COMPLETED	Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)
NCT00456508	PHASE3	COMPLETED	Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
NCT00457015	PHASE3	COMPLETED	Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)
NCT01253382	PHASE2/PHASE3	WITHDRAWN	Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema
NCT00448864	PHASE2	TERMINATED	Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement
NCT00816023	PHASE2	COMPLETED	A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume
NCT00888940	PHASE2	COMPLETED	Outcomes and Safety Trial Investigating Ecallantide’s Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery
NCT01343823	PHASE2	TERMINATED	Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
NCT01826916	PHASE2	COMPLETED	EDEMA2: Evaluation of DX-88’s Effect in Mitigating Angioedema
NCT01832896	PHASE2	WITHDRAWN	Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema
NCT01059526	Not specified	COMPLETED	Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).